Changes in Hong Kong stocks | Pharmaceutical stocks are mostly rising, and the industry has recently welcomed a number of catalytic institutions that are optimistic about the sector and there is room for further repair

The Zhitong Finance App learned that most pharmaceutical stocks were higher. As of press release, Lai Kai Pharmaceutical-B (02105) rose 32.9% to HK$8.2; Yiming Onko-B (01541) rose 21.93% to HK$6.06; Yasheng Pharmaceutical-B (06855) rose 6.31% to HK$47.2; Zaiding Pharmaceutical (09688) rose 4.57% to HK$20.35.

According to the news, the 2024 health insurance negotiations are about to enter the negotiation/bidding stage. According to SDIC Securities, a total of about 41 domestically produced exclusive innovative drugs (including introduction) have passed the formal review in the current health insurance negotiations, and it is expected that additional drug negotiations will be added: including 28 innovative drugs newly approved for marketing between July 1, 2023 and June 30, 2024, and 13 innovative drugs approved for marketing before July 1, 2023. The bank believes that the national negotiations have entered the normalization stage, and the long-term release of innovative drugs can be expected.

According to BOC International, the tenth batch of national drug procurement reports shows that the entry threshold for this round of national procurement is the highest in history, and injections account for the highest proportion in history. It is expected that competition will be extremely intense, but for most prescription pharmaceutical companies, there are few large varieties involved, and the impact may be limited. The recommendation is based on the final variety list. Recently, the pharmaceutical sector has fluctuated sharply due to fluctuations in market investment sentiment, but considering that the previous sector's valuation was at a historical bottom, the bank believes there is still room for further restoration. Zhongtai Securities said that looking ahead to the second half of the year, it is expected that the entire chain will continue to advance in support of innovative drugs, equipment upgrades, and basic drug catalogues; health insurance negotiations, major meetings in the field of innovative drugs such as the ESMO/WCLC/ASH/American Academy of Ophthalmology annual conference, and the promotion of GLP-1 research and development are expected to catalyze.